Cargando…
An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor– positive early breast cancer
The third-generation aromatase inhibitors (AIS) are largely replacing tamoxifen in the adjuvant treatment of early-stage breast cancer in postmenopausal women with hormone receptor–positive tumours. To date, multiple trials have been conducted comparing tamoxifen treatment with an AI, and all have d...
Autores principales: | Verma, S., Sehdev, S., Joy, A., Madarnas, Y., Younus, J., Roy, J. A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Multimed Inc.
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722048/ https://www.ncbi.nlm.nih.gov/pubmed/19672416 |
Ejemplares similares
-
Safety of adjuvant endocrine therapies in hormone receptor–positive early breast cancer
por: Sehdev, S., et al.
Publicado: (2009) -
Extended adjuvant endocrine therapy for women with hormone receptor-positive early breast cancer: A meta-analysis with trial sequential analysis of randomized controlled trials
por: Xie, Ming, et al.
Publicado: (2022) -
Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer
por: Towns, K., et al.
Publicado: (2008) -
Relative dose intensity delivered to patients with early breast cancer: Canadian experience
por: Raza, S., et al.
Publicado: (2009) -
Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials
por: Hu, Qiancheng, et al.
Publicado: (2023)